focus -WSS

focus

author：focus 2025-09-30 16:29:44 - browse：32958

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： The strategy behind pharma's lawsuits over drug pricing reform

WSS

Biotech reporter’s notebook: A sunnier mood at JPM 2024

What would happen to your eyes if you looked at the solar eclipse?

Readout LOUD podcast: live from JPM 2024

Why are elite athletes different? Take a look at their microbes

Disclosing genetic information: not as worrisome as once feared

Designating disabled people as health disparity population is crucial

hotspot

focus

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Idaho abortion case may prompt more restrictions in other states

State Dept. review finds Biden bears some blame for Afghanistan failures

Designating disabled people as health disparity population is crucial

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD podcast: live from JPM 2024

The cancer drug shortage isn’t new — and neither are the solutions

As JPM 2024 winds down, some health tech firms project optimism

BioMarin wins approval for gene therapy to treat hemophilia A

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

focus

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

The battle over the Brookhaven Landfill on Long Island

Why are elite athletes different? Take a look at their microbes

Generative AI mines health records to identify patients’ social needs

Idaho abortion case may prompt more restrictions in other states

Wikipedia

explore

leisure time

leisure time